Aileron

Aileron Therapeutics, a biopharma company developing therapies based on a stapled peptide platform, has announced the expansion of its senior management team with the appointment of Manuel Aivado as Chief Medical Officer, and Donna Jarlenski as VP of Clinical Operations and Project Management.

The announcement accompanies the news that Aileron has secured a total of $48m in Series E equity financing. The extra $33m announced this week comes from three new investors, including AJU IB Investment Co and two undisclosed private investment groups.

The proceeds will be used to advance ALRN-6924 into clinical trials – a re-activator of p53, a tumour suppressor protein that works on both liquid and solid tumours. 

Stapled Peptides are an emerging class of drugs which attack the critical drivers of complex diseases, including cancer, endocrine/metabolic disorders and infectious diseases. Aileron’s platform locks peptides into their biologically active shape and makes them more stable.